507473-22-5 Usage
General Description
2,3-dimethoxy-5-nitropyridine is a chemical compound with the molecular formula C7H8N2O4. It is a pyridine derivative with two methoxy groups and a nitro group attached to the aromatic ring. 2,3-dimethoxy-5-nitropyridine is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is a yellow crystalline solid that is relatively stable under normal conditions. 2,3-dimethoxy-5-nitropyridine is also known for its mild toxicity and should be handled with care. It is important to follow proper safety precautions when working with this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 507473-22-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,7,4,7 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 507473-22:
(8*5)+(7*0)+(6*7)+(5*4)+(4*7)+(3*3)+(2*2)+(1*2)=145
145 % 10 = 5
So 507473-22-5 is a valid CAS Registry Number.
507473-22-5Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
-
Paragraph 00245; 00287-00288, (2020/08/13)
The present invention relates to compounds that modulate cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion, by modulating protein kinase enzymatic activity, and compositions thereof, and methods of using such compounds.
Indole compound as well as preparation method, pharmaceutical composition and application thereof
-
Paragraph 1635-1640, (2019/12/02)
The invention discloses an indole compound as well as a preparation method, a pharmaceutical composition and an application thereof. Specifically, the invention relates to an indole derivative as shown in a general formula I and a medicinal salt thereof, a preparation method of the indole derivative, a composition containing one or more compounds, and applications of the compounds in preparation of medicines for preventing and/or treating diseases related to IDO1 and/or TDO.
